Transfusion Camp in Rwanda 2023 – Train the Trainer Camp
Seminar 1: Triggers for RBC and platelet transfusions

Please start session by asking trainees if they have any questions from the didactic sessions.

Please remind trainees that although one answer is bolded as the correct answer, there may be more than one reasonable answer to the questions. The purpose of the seminar is to promote discussion and explore why certain answers may be more appropriate in certain situations.

Case 1

A 70 year old male is admitted to the ICU with respiratory failure due to pneumococcal pneumonia. His past medical history is significant for coronary artery disease but he has been asymptomatic since undergoing bypass operation approximately 5 years ago. He is on antibiotics and is hemodynamically stable. He is intubated and ventilated (PS10, PEEP 8, FiO2 0.5, oxygen saturation 94%). There is no evidence of bleeding or hemolysis. However, over the last few days his hemoglobin concentration has drifted down to 7.9 g/dL.

1) Which of the following represents the most appropriate RBC transfusion strategy for this patient?
   A) Transfuse RBCs if Hgb <10 g/dL
   B) Transfuse RBCs if Hgb <9 g/dL
   C) Transfuse RBCs if Hgb <8 g/dL
   D) Transfuse RBCs if Hgb <7 g/dL

This patient does not currently require an RBC transfusion. Red blood cells are transfused to increase oxygen delivery to the tissues. Studies have healthy volunteers show hemoglobin levels as low as 5 g/dL are well tolerated so long as perfusion (ie., intravascular volume) was maintained. The ability to tolerate anemia depends on the patient’s age, co-morbidities and clinical situation. Symptoms of tissue hypoxia are non-specific and may include: fatigue, lightheadedness, chest pain, shortness of breath and presyncope. Assessment of tissue hypoxia may be challenging in a critically ill patient.

The results of the TRICC (Transfusion Requirements in Critical Care) randomized controlled trial are directly applicable to this patient. In this study, 838 euvolemic ICU patients with hemoglobin < 9 g/dL were randomized to two different transfusion strategies: restrictive (transfuse only if Hgb < 7 g/dL) versus liberal (transfuse only if Hgb < 10 g/dL). There was no difference in 30 day mortality (18.7 vs 23.3%), suggesting that the restrictive strategy was safe. In fact, patients randomized to a restrictive transfusion strategy had a lower likelihood of dying before discharge (22.2 vs 28.1%, p = 0.05).

Important exclusion criteria for the TRICC trial were patients with active bleeding, and patients who were admitted after a routine cardiac procedure. In addition, while subgroup analysis did not reveal any

---

advantage of a liberal transfusion strategy in patients with a history of cardiac disease, such patients represented only a quarter of those who were enrolled. Therefore, caution should be exercised in generalizing the findings of the TRICC trial to patients with chronic anemia, active bleeding, or cardiac disease. Subsequent studies of a restrictive transfusion strategies in these populations have therefore sometimes used a higher transfusion threshold of 7.5 or 8 g/dL. However, the results of the great majority of these trials have still shown that a restrictive strategy is at least as safe as a liberal approach. The literature on different Hgb thresholds for RBC transfusion is well summarized in the recent evidence-based AABB\textsuperscript{2} and ICC-PBM\textsuperscript{3} guidelines (Mueller et al, JAMA 2019):

- The following restrictive RBC transfusion thresholds are recommended as per AABB guidelines:
  - Transfusion is not indicated until the hemoglobin level is 7 g/dL for hospitalized adult patients who are hemodynamically stable, including critically ill patients
  - For patients undergoing orthopedic or cardiac surgery and those with preexisting cardiovascular disease, use transfusion threshold of 80 g/dL
  - These recommendations do not apply to patients with acute coronary syndrome, severe thrombocytopenia (patients treated for hematological or oncological reasons who are at risk of bleeding), and chronic transfusion–dependent anemia

- The following restrictive RBC transfusion thresholds are recommended as per the ICC-PBM guidelines:

<table>
<thead>
<tr>
<th>Clinical Recommendation</th>
<th>Level of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR5—Restrictive RBC transfusion threshold (hemoglobin concentration &lt;7 g/dL) in critically ill but clinically stable intensive care patients</td>
<td>Strong recommendation, moderate certainty in the evidence of effects</td>
</tr>
<tr>
<td>CR6—Restrictive RBC transfusion threshold (hemoglobin concentration &lt;7.5 g/dL) in patients undergoing cardiac surgery</td>
<td>Strong recommendation, moderate certainty in the evidence of effects</td>
</tr>
<tr>
<td>CR7—Restrictive RBC transfusion threshold (hemoglobin concentration &lt;8 g/dL) in patients with hip fracture and cardiovascular disease or other risk factors</td>
<td>Conditional recommendation, moderate certainty in the evidence of effects</td>
</tr>
<tr>
<td>CR8—Restrictive RBC transfusion threshold (hemoglobin concentration &lt;7-8 g/dL) in hemodynamically stable patients with acute gastrointestinal bleeding</td>
<td>Conditional recommendation, low certainty in the evidence of effects</td>
</tr>
</tbody>
</table>

Abbreviations: CR, clinical recommendation; RBC, red blood cell.

- Further research on RBC transfusion support in patients with hematologic and oncologic diseases, coronary heart diseases, noncardiac or nonorthopedic surgery, or brain injury is ongoing. Note that a recently published randomized controlled trial of RBC transfusion in patients with thrombocytopenia in the setting of stem cell transplantation did not find that maintaining a higher hemoglobin level through liberal transfusion helped decrease the risk of bleeding.\textsuperscript{4}

Another important exclusion from the TRICC trial was patients with chronic anemia. Subsequently published RCTs have suggested that in these patients, even a hemoglobin less than 7 g/dL can be well

tolerated. The World Health Organization recommends not performing transfusions in African children hospitalized for uncomplicated severe anemia (hemoglobin level of 4 to 6 g/dL and no signs of clinical severity), a strategy supported by a recently published randomized controlled trial. Most of the children in this study had malarial anemia; patients with sickle cell disease were excluded. Given the complexity and risk of transfusion decisions in patients with hemoglobinopathies, transfusions should only be ordered for this population in consultation with a hematologist.

In general, given the cost, risk and scarcity of blood, an RBC transfusion should only be pursued if the patient truly requires an increase in their hemoglobin, and an RBC transfusion is the only option to accomplish that.

2) Which of the following strategies may minimize the patient’s need for future RBC transfusion?
   A) Minimize unnecessary diagnostic phlebotomy
   B) Start an erythropoiesis stimulating agent
   C) Start B12 supplementation
   D) Start iron supplementation

Anemia is common in critically ill patients and is frequently treated with RBC transfusions, even in the absence of bleeding. For example, 44% of patients received at least one RBC transfusion while they were admitted, with only 24% transfused to treat active bleeding. This patient’s anemia is likewise not apparently due to bleeding and is likely a result of both frequent phlebotomies for laboratory testing and inhibited erythropoiesis from inflammation and malnutrition. The ICU team may therefore consider the following strategies: reduce unnecessary phlebotomies, prescribe an erythropoiesis-stimulating agent (ESA) such as erythropoietin, or provide increased nutritional support (ie., iron, B12, or folate supplements).

The benefits of ESA therapy in critically ill patients are marginal. A 2007 meta-analysis of 9 randomized controlled trials did find that critically ill patients prescribed an ESA had their risk of transfusion decreased by approximately 25%; however, the average number of RBCs transfused was only 0.41 units less than amongst patients not prescribed an ESA. Had these patients all been managed with a restrictive transfusion strategy, the benefit of ESA would likely have been even smaller. Given the cost and potential risk of thrombosis, ESA treatment is rarely indicated in critically ill patients.

There is little evidence that iron supplementation is of benefit in this setting as well. In a randomized controlled trial of IV iron in 150 patients with anemia in the setting of traumatic critical illness, no effect was observed on hemoglobin levels or transfusion requirements, despite the fact that the majority had evidence of iron-restricted erythropoiesis. Given the cost and increased risk of infection that

accompanies IV iron therapy,⁸ its use cannot be advocated in critically ill patients. Importantly, however, less than 2% of patients enrolled in this study had serum ferritin levels < 28 µg/L, indicating true iron deficiency. In such patients, iron repletion therapy may still be of some benefit. B12 deficiency is so rare in critically ill patients that routine supplementation cannot be justified.⁹

Preventing iatrogenic anemia is therefore the best course of action and A is thus the best answer. Multiple studies have shown that patients admitted to hospital routinely lose 50 mL or more of blood per day to samples drawn for laboratory testing.¹⁰ Strategies that have been shown to decrease the amount of phlebotomy losses include the use of devices that return blood from testing or flushing lines to the patient, and transition to small volume tubes for lab tests. These tubes are of the same size and cost the same; however they have less vacuum and as a result, draw 25-50% less blood into the tube.¹¹ The most effective strategy, however, is to avoid the reflexive ordering of laboratory testing which is unlikely to provide new or useful information for the management of the patient.

3) You review the patient’s laboratory results and notice that his troponin is significantly elevated. Troponin was ordered to further investigate an episode of rapid atrial fibrillation and ST changes earlier in the morning. Which one of the following represents the best transfusion strategy for this patient?

A) No transfusion is needed at this time
B) Transfuse 1 unit RBC rapidly
C) Transfuse 1 unit RBC over 3 hours
D) Transfuse 2 units RBC rapidly

The impact of red blood cell transfusion on outcomes in patients with acute coronary syndrome is controversial. A 2018 systematic review examined the association between blood transfusion and the risk for all-cause mortality and reinfarction, drawing data from 17 observational studies, 2 525 550 subjects, and follow-up period ranging from 30 days to 5 years.¹² Red blood cell transfusion (compared with no blood transfusion) was associated with higher short- and long-term all-cause mortality as well as reinfarction rates (adjusted RR 2.23 and 2.61, respectively). In hemoglobin-stratified analyses, a graded association between red blood cell transfusion and mortality was observed, transfusion and risk of all-cause mortality was borderline significant at hemoglobin levels below 8 g/dL (RR 0.52), and was associated with an increased risk of mortality at a hemoglobin above 10 g/dL (RR 3.34). The authors concluded that transfusion had beneficial or neutral effects on mortality at hemoglobin levels below 8 g/dL, and harmful effects above 10 g/dL. This review suggests that there is no absolute threshold and the optimal, evidence-based approach has not been yet determined. The recently published RCT REALITY has shown that in patients with AMI restrictive transfusion strategy (Hgb 8 g/dL or below) was

---

non-inferior to liberal strategy (Hgb 10 g/dL or below).\textsuperscript{13} A large definitive randomized controlled trial addressing this issue is underway (MINT): 3 500 patients with AMI randomized to restrictive strategy (Hgb less than 8 g/dL) versus liberal strategy (Hgb less than 10 g/dL).

A reasonable approach in this situation would be to transfuse when Hgb <8 g/dL, one unit of RBC at a time and at a slow rate to prevent volume overload while frequently reassessing symptoms. Transfusion of RBC beyond hemoglobin of 10 g/dL may be harmful.

**Case 2**

25 year old female with no significant past medical history, is seen in the emergency room with “a critically abnormal laboratory result”, a hemoglobin of 6 g/dL. She has a long-standing history of menorrhagia and was sent to the ER by her family MD. On questioning, she endorses fatigue and reduced stamina but remains active and continues working full time. Her CBC reveals Hgb 6 g/dL, MCV 65 fl, platelets 487 x 10\textsuperscript{9}/L, coagulation studies are normal.

4) Which of the following represents the least appropriate intervention?
   
   A) Intravenous iron  
   B) Oral iron  
   C) Referral to gynecology  
   D) Transfusion of RBC

This patient likely has iron deficiency anemia related to her menorrhagia. Because of the chronicity of the problem, she is only minimally symptomatic. Diagnosis of IDA can be confirmed by ordering iron studies. IDA is the most common nutritional deficiency anemia, and an estimated 10-40% of women are iron deficient.

This patient does not require a transfusion. In addition to usual risks associated with transfusion, consider the risk of RBC antigen alloimmunization in a young, potentially child-bearing woman; and volume overload since her anemia is euvelemic. Do not transfuse RBC unless clear and worrisome symptoms of anemia (tachycardia, hypotension, chest pain, shortness of breath, pre-syncope).

She should be referred to hematology for anemia management and perhaps to rule out a bleeding disorder, and to gynecology to manage her menorrhagia. She should receive iron – either oral or intravenous. The advantages of oral iron are reduced cost and ability to take at home, but absorption is poor (only 10% of the elemental iron taken by mouth is actually absorbed), meaning that replenishment is very slow.

Oral iron also causes gastrointestinal side effects, which is a common cause of non-compliance. Newer oral iron formulations appear to be inferior to older ferrous salt formulations. Ferrous salts improve hemoglobin up to 2 g/dL more with one in five more attaining iron deficiency anemia resolution at 3-

months. Evidence that newer formulations have less adverse effects is also inconsistent and not supported by published literature.14

Intravenous iron has the advantage of much more rapid treatment – depending on the formulation used, a total target dose of 1 gram of iron can be administered over 1 to 3 infusions. However, it is more expensive than oral iron and requires a healthcare worker to administer and monitor. Side effects include15

- Metallic taste, headache, nausea, vomiting, diarrhea, abdominal pain, back pain, muscle cramps, arthralgias, infusion site reactions
- Fishbane reaction (facial flushing, myalgia, arthralgia, chest pain)
- Hypersensitivity reaction including anaphylaxis

Case 3

A 2 year-old female is seen because of pallor and her mother feels that she is less active than the other toddlers. Nutritional history indicates that the child is no longer breast feeding and her diet consists primarily of maize porridge. There is no history of fever and no splenomegaly on examination. CBC shows hemoglobin 7.9 g/dL, MCV 72 fL, WBC 7.9 x 10^9/L, platelets 475 x 10^9/L.

5) Which of the following is the most appropriate management of this child’s anemia?
   A) Empiric treatment of malaria, followed by IV iron weekly for 6 weeks
   B) Resume breastfeeding
   C) Provide nutritional consultation and oral iron supplementation
   D) Transfuse a weight-based dose of RBCs

Iron deficiency in children is very common in many parts of Africa, and has been estimated to affect approximately 1 in 5 children under age two in Southern Rwanda.16 Studies show that iron deficiency in children is associated with learning disabilities. Causes include poor diet, low iron content in the soil where crops are grown, and malabsorption secondary to intestinal parasites, or chronic inflammation (eg., recurrent malaria). Improving dietary iron (eg., introduction of fish or other animal protein sources) and providing iron supplements, typically at a dose of 3-6 mg/kg per day of elemental iron for 3 months, is the preferred treatment. A meta-analysis found little evidence that augmenting oral iron intake increases the risk of malaria in children living in endemic areas.17 Whether or not the same is true for intravenous infusions of iron, the cost and inconvenience of arranging them is probably not justified in this case. Similarly, while transfusing RBCs will result in the most rapid increase in hemoglobin of all the above options, the cost and risk is not justified for this degree of anemia. Finally, while breastmilk is an important source of iron for newborns, and is much superior to cow’s milk, it is

generally insufficient to meet nutritional needs after 6 months of age and cannot be relied upon as a treatment of this child’s iron deficiency.18

Case 4

A 27 year-old man with acute myeloid leukemia is admitted for induction chemotherapy. He is afebrile. He denies bleeding but examination reveals numerous petechiae on his lower extremities and a few large ecchymoses on his extremities and trunk. Morning CBC reveals Hgb 7.3 g/dL and platelets 5 x 10^9/L. Review of his recent CBC results indicates that his platelet count has not been above 10 for the past two weeks, despite being transfused platelets two to three times per week.

6) In addition to investigating the cause of the patient’s high platelet transfusion requirements, which one of the following is the most appropriate transfusion strategy for this patient?

A) Only transfuse platelets in the presence of active bleeding
B) Start the patient on tranexamic acid
C) Transfuse 1 adult dose of platelets today
D) Transfuse 2 adult doses of platelets today

Platelet transfusion guideline is provided below:

<table>
<thead>
<tr>
<th>Platelet count (x 10^9/L)</th>
<th>Clinical Setting</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 10</td>
<td>Hypoproliferative (eg., not ITP, DIC, etc)</td>
<td>Transfuse 1 adult dose</td>
</tr>
<tr>
<td>&lt; 20</td>
<td>Procedures not associated with significant blood loss (eg., central line placement)</td>
<td>Transfuse 1 adult dose</td>
</tr>
<tr>
<td>&lt; 30</td>
<td>Patients on anticoagulants that must remain at full dose (eg., proximal leg DVT &lt; 30 days ago)</td>
<td>Transfuse 1 adult dose</td>
</tr>
<tr>
<td>20 - 50</td>
<td>Procedures not associated with significant blood loss (eg., central line placement)</td>
<td>Have 1 adult dose on hand but only transfuse if significant bleeding</td>
</tr>
<tr>
<td>&lt; 50</td>
<td>1. Significant bleeding, or 2. Prior to major surgical procedures</td>
<td>Transfuse 1 adult dose immediately pre-procedure</td>
</tr>
<tr>
<td>&lt; 50</td>
<td>Immune thrombocytopenia</td>
<td>Transfuse 1 adult dose only if life-threatening bleeding</td>
</tr>
<tr>
<td>&lt; 100</td>
<td>1. Neurosurgical procedure 2. Traumatic brain injury/intracranial hemorrhage</td>
<td>Transfuse 1 adult dose</td>
</tr>
<tr>
<td>Any</td>
<td>Platelet dysfunction with significant hemorrhage (eg., post-cardiopulmonary bypass)</td>
<td>Transfuse 1 adult dose</td>
</tr>
</tbody>
</table>

In the above table, one adult dose of platelets refers to a pool of platelet concentrates obtained from 4-6 whole blood donations, or a platelet product collected by apheresis. Either way, the total number of platelets in an adult dose is typically 3 x 10^{11}/L in approximately 300 mL of plasma. The majority of these recommendations are based on expert opinion and are not evidence based. However, randomized controlled trials have established that in patients with hypoproliferative thrombocytopenia (ie., not due to immune thrombocytopenia), transfusing platelets

prophylactically whenever the platelet count is < 10 x 10⁹/L decreases the risk of spontaneous bleeding, and the risk of spontaneous bleeding increases the longer the platelet count is below this threshold.¹⁹ Therefore, unless this patient’s platelet count is expected to increase on its own in the next few days, withholding platelet transfusion is likely to increase the risk of bleeding; in certain circumstances, such as the presence of fungal pneumonia, this bleeding may be fatal.²⁰ On the other hand, several trials have shown that there is no clinical benefit in prophylactically transfusing hypoproliferative thrombocytopenia at thresholds higher than 10 x 10⁹/L, or with using larger than standard doses of platelets.²¹ Tranexamic acid may be considered an alternative to platelet transfusions in thrombocytopenic patients for whom platelet products are unavailable. However, there is no evidence to date that this results in equivalent hemostasis; in fact, adding tranexamic acid to prophylactic platelet transfusions doesn’t appear to provide any increment benefit.²²

7) You suspect that he has developed platelet transfusion refractoriness due to antiplatelet antibodies. Which one of the following investigations is least likely to help you determine the cause of the refractoriness?

A) Bone marrow aspirate and biopsy  
B) HLA antibody screen  
C) Panculture to look for occult infection  
D) Platelet count measured one hour post platelet transfusion

Platelet refractoriness is a persistent lack of response to platelet transfusion. It may result from non-immune factors (majority of cases: sepsis, splenomegaly, medications, thrombosis, DIC, bleeding) vs. immune factors (minority of cases: alloimmunization to human leukocyte antigens (HLA), human platelet antigens (HPA), or both, or other platelet antigens). To distinguish which is occurring, the preferred investigation is to select a relatively fresh (eg., less than 4 days from time of collection) and ABO identical platelet product and then measure the patient’s platelet increment no more than hour after transfusion. Even when removing the confounding effects of ABO group and product age, the observed increment will still vary depending on how many platelets are transfused and the patient’s body surface area, and the formula for a corrected count increment incorporates for those factors. However, an average adult-dose of platelets transfused to an average adult patient should cause the platelet count to increase by at least 10 10⁹/L. If the platelet count hasn’t increased by at least this much even an hour after transfusion, it is very likely that the patient has immune-mediated platelet refractoriness, due to either autoantibodies (ie., immune thrombocytopenia) or alloantibodies to HLA or HPA antigens. A variety of methods are available to detect these antibodies, but are rarely available at the local hospital and will therefore need to be referred out. Once confirmed, the blood supplier may be able to select platelet products that are matched for those antibodies. However, the entire process may take a week or longer, and therefore investigations should start as soon as refractory thrombocytopenia is observed.

²² Gernsheimer TB, Brown SP, PhD, Triulzi DJ, MD, Blood 2020.136 (Supp 1): 1–2
8) The patient is transitioned to ABO-identical, fresh platelets and on two occasions the 1-hour increment in platelet count was < 10^9/L. A sample of patient plasma is sent to a referral laboratory to assess for anti-HLA antibodies, and the blood supplier is notified that HLA-matched platelets may be required, if available. Which one of the following is the least appropriate management strategy while awaiting arrival of HLA-selected platelets?
   A) Give IVIg 1g/kg daily
   B) Give oral tranexamic acid to treat minor bleeding
   C) Transfuse pooled, ABO compatible and freshest available platelets
   D) Transfuse platelets only to treat clinically significant bleeding

Patients with alloimmune refractoriness should be managed with HLA selected platelets. Often HLA selected platelets are referred to as HLA matched platelets but these two products are different. HLA selected platelets are antigen negative for the HLA antibodies which the patient has developed, and not necessarily HLA matched for the patient’s HLA phenotype, and may therefore provoke the appearance of other antibodies. However, they are often easier to source than HLA-matched platelets and should be selected if that is the only product available. If even HLA-selected products aren’t selected, the best odds of avoiding the patient’s HLA antibodies are to select products pooled from several donors, while also minimizing the clearance that accompanies ABO-mismatched or older platelet products. If these continue to produce even a short-term increment in platelet count, then there is no point in transfusing prophylactically, and platelet transfusion should be attempted only for treatment of serious bleeding. Minor bleeding may be managed with tranexamic acid. Immunomodulation with IVIG, steroids, etc. to manage alloimmune refractoriness is ineffective and is not recommended, unless there is suspicion that the patient has an autoantibody (ie, immune thrombocytopenia)

**Case 5a**

A 69 year old male is admitted via ER with acute subdural hematoma following a fall. He is known to have liver cirrhosis due to alcohol. His CBC revealed Hgb 12.5 g/dL and platelets 75 x 10^9/L. His INR was 1.3. He is scheduled for a burr hole surgery later this evening.

9) Which one of the following represents the most appropriate transfusion strategy?
   A) No need for platelet transfusion
   B) Transfuse 1 adult dose of platelets and repeat CBC
   C) Transfuse 1 adult dose of platelets only if significant intra-operative bleeding
   D) Transfuse 2 adult doses of platelets

See answer to question 1, case 1 above. Even though not based on evidence, usually platelet transfusion is recommended for patients going for neurosurgical procedures/intracerebral bleeding to maintain platelet count above 100 x 10^9/L. Transfuse 1 adult dose of platelets and monitor clinically for bleeding and with regular CBC. In this situation, the platelet count may not increase, or may decrease very rapidly, due to the presence of splenomegaly from the patient’s portal hypertension. If this is observed, it may not be necessary to repeatedly transfuse platelets to achieve a platelet count of 100 x10^9/L, especially since the platelets sequestered in an enlarged spleen are often still viable and can be released back into circulation (eg., in response to epinephrine), where they can contribute to hemostasis.23

---

Case 5b

An 80 year-old male on aspirin and clopidogrel presents with spontaneous ICH. His GCS is 15 and no surgical intervention is planned. His platelet count is 249 x 10^9/L and INR and aPTT are normal.

10) Which one of the following is the most appropriate therapy?
   A. 1 adult dose of platelets
   B. 2 adult doses of platelets
   C. PCC 50IU/kg IV and Vitamin K 10 mg IV
   D. None of the above

Platelet transfusion can be used to reverse the effects of anti-platelet drugs. Clopidogrel is an oral pro-drug and its active metabolite irreversibly binds and inhibits the ADP receptor P2Y12 thus blocking platelet activation. The plasma half-life of this drug is 7-8 hours while the half-life of its active metabolite is less than 1 hour. However, its antiplatelet effect can last for up to 5 days. There are no reliable, readily available tests to diagnose Clopidogrel-associated platelet dysfunction. There are also no clinical studies examining efficacy of platelet transfusions to manage bleeding in the setting of a platelet dysfunction due to antiplatelet agents. Most studies to date have assessed the effect of antiplatelet agents by measuring in vitro platelet function pre and post transfusion of normal donor platelets, and it is not clear if these results translate to in vivo clinical outcomes. The PATCH trial, in fact, has shown that transfusing platelets to reverse the effect of drug-induced thrombasthenia can actually worsen outcomes. In this randomized controlled trial, patients on antiplatelet medications with spontaneous intracerebral hemorrhage, actually had a higher rate of bleeding (25% vs 14%) as well as thrombotic complications (4% vs 1%) if they were transfused platelets, results that were accompanied by an overall worse functional status and mortality rate. In view of this trial, routine transfusion of platelets in this situation is not recommended. Although this study was limited to patients with spontaneous intracranial hemorrhage, caution should be exercised when transfusing platelets to thrombasthenic patients with other types of bleeding (eg., peptic ulcers in patients taking NSAID therapy). Whenever possible, surgical control of bleeding should be prioritized in these patients.